KIT and small cell lung carcinoma: Although several preclinical studies reported that suppression of c-kit signaling inhibits SCLC cell growth [4], [11], phase II imatinib trials in patients with relapsed c-kit-positive SCLC reported no objective responses or sustained disease stabilization [12], [13], [14].